Bio-Techne Corporation (TECH) Income Statement
TECH FY2026 at a glance
Fiscal year ended June 30, 2026 · U.S. dollarsTECH revenue and net income
Where TECH's revenue goes
FY2026Each bar shows an amount and its share of revenue. TECH kept 15.0% of revenue as net income.
TECH profit margins
TECH growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −0.4% | +2.2% | +5.5% | +9.3% |
| Gross profit | +1.1% | +1.3% | +4.8% | +9.0% |
| Operating income | +146.3% | −5.5% | +1.2% | +5.3% |
| Net income | +147.8% | −13.9% | +5.3% | +5.7% |
| EPS (diluted) | −4.7% | −2.7% | +1.7% | +7.4% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TECH quarterly EPS vs estimates
Bio-Techne beat the analyst EPS estimate in 8 of the last 8 quarters. Next report: November 4, 2026 (estimate $0.40).
TECH income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.22B | $1.22B | $1.16B | $1.14B | $1.11B | $931.0M | $738.7M | $714.0M | $643.0M | $563.0M |
| Cost of revenue | $416.0M | $429.4M | $389.3M | $366.9M | $349.1M | $298.2M | $255.5M | $240.5M | $210.8M | $188.5M |
| Gross profit | $799.1M | $790.3M | $769.7M | $769.8M | $756.5M | $632.9M | $483.2M | $473.5M | $432.1M | $374.5M |
| Research & development | $94.8M | $99.5M | $96.7M | $92.5M | $87.1M | $70.6M | $65.2M | $62.4M | $55.3M | $53.5M |
| Sales, general & admin | $452.4M | $415.1M | $462.9M | $378.4M | $372.8M | $325.0M | $260.6M | $264.4M | $240.6M | $199.2M |
| Total operating expenses | $547.2M | $688.0M | $563.0M | $470.9M | $459.9M | $395.6M | $325.8M | $326.8M | $296.0M | $252.8M |
| Operating income | $251.9M | $102.3M | $206.7M | $298.9M | $296.6M | $237.3M | $157.4M | $125.6M | $136.2M | $121.8M |
| Interest income | $4.2M | $3.9M | $3.3M | $3.4M | $794,000 | $473,000 | $605,000 | $569,000 | $409,000 | $304,000 |
| Interest expense | $5.4M | $8.5M | $15.7M | $11.2M | $11.3M | $14.0M | $19.2M | $21.7M | $10.2M | $7.4M |
| Income before taxes | $240.7M | $98.5M | $185.7M | $338.7M | $301.4M | $148.2M | $276.5M | $112.0M | $126.0M | $113.2M |
| Income taxes | $58.8M | $25.1M | $17.6M | $53.2M | $38.3M | $8.6M | $47.2M | $15.9M | $602,000 | $35.9M |
| Net income | $181.9M | $73.4M | $168.1M | $285.3M | $272.1M | $140.4M | $229.3M | $96.1M | $125.3M | $77.3M |
| EBITDA | $343.4M | $216.9M | $313.1M | $457.1M | $413.8M | $249.9M | $378.4M | $211.9M | $200.6M | $181.8M |
| EPS (diluted) | $1.84 | $1.93 | $1.78 | $2.00 | $1.98 | $1.69 | $1.14 | $1.13 | $1.13 | $0.92 |
| Gross margin | 65.8% | 64.8% | 66.4% | 67.7% | 68.4% | 68.0% | 65.4% | 66.3% | 67.2% | 66.5% |
| Operating margin | 20.7% | 8.4% | 17.8% | 26.3% | 26.8% | 25.5% | 21.3% | 17.6% | 21.2% | 21.6% |
| Net margin | 15.0% | 6.0% | 14.5% | 25.1% | 24.6% | 15.1% | 31.0% | 13.5% | 19.5% | 13.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $321.2M | $311.4M | $295.9M | $286.6M | $317.0M | $316.2M | $297.0M | $289.5M | $306.1M | $303.4M | $272.6M | $276.9M |
| Cost of revenue | $109.8M | $103.1M | $104.6M | $98.4M | $118.2M | $101.6M | $103.1M | $106.4M | $102.8M | $98.8M | $96.0M | $91.7M |
| Gross profit | $211.4M | $208.3M | $191.3M | $188.1M | $198.8M | $214.6M | $193.9M | $183.0M | $203.3M | $204.6M | $176.6M | $185.2M |
| Research & development | $23.9M | $23.5M | $23.1M | $24.2M | $26.0M | $24.6M | $25.0M | $23.9M | $24.0M | $25.8M | $22.9M | $24.0M |
| Sales, general & admin | $113.2M | $109.3M | $113.7M | $116.2M | $23.2M | $151.3M | $121.5M | $119.2M | $64.0M | $111.8M | $115.7M | $105.3M |
| Total operating expenses | $137.1M | $132.8M | $136.8M | $140.5M | $222.7M | $175.8M | $146.5M | $143.0M | $157.5M | $137.6M | $138.6M | $129.3M |
| Operating income | $74.3M | $75.5M | $54.5M | $47.7M | −$23.9M | $38.7M | $47.4M | $40.0M | $45.8M | $67.0M | $38.0M | $55.9M |
| Interest income | $1.4M | $981,000 | $897,000 | $971,000 | $585,000 | $1.0M | $1.3M | $926,000 | $905,000 | $712,000 | $816,000 | $890,000 |
| Interest expense | $2.9M | $3.2M | $2.2M | $2.9M | $2.2M | $2.0M | $2.1M | $2.2M | $2.5M | $4.0M | $4.3M | $4.9M |
| Income before taxes | $70.7M | $71.2M | $50.8M | $48.0M | −$22.9M | $38.3M | $42.9M | $40.2M | $41.7M | $61.1M | $33.4M | $49.6M |
| Income taxes | $16.1M | $20.2M | $12.8M | $9.8M | −$5.2M | $15.7M | $8.0M | $6.6M | $1.1M | $12.0M | $5.9M | −$1.4M |
| Net income | $54.6M | $51.1M | $38.0M | $38.2M | −$17.7M | $22.6M | $34.9M | $33.6M | $40.6M | $49.1M | $27.5M | $51.0M |
| EBITDA | $91.9M | $98.6M | $77.7M | $75.3M | $6.4M | $67.9M | $72.1M | $70.5M | $72.2M | $92.4M | $65.5M | $83.0M |
| EPS (diluted) | $0.49 | $0.53 | $0.46 | $0.36 | $0.53 | $0.56 | $0.42 | $0.42 | $0.49 | $0.48 | $0.40 | $0.41 |
| Gross margin | 65.8% | 66.9% | 64.6% | 65.6% | 62.7% | 67.9% | 65.3% | 63.2% | 66.4% | 67.4% | 64.8% | 66.9% |
| Operating margin | 23.1% | 24.2% | 18.4% | 16.6% | −7.5% | 12.2% | 16.0% | 13.8% | 15.0% | 22.1% | 13.9% | 20.2% |
| Net margin | 17.0% | 16.4% | 12.8% | 13.3% | −5.6% | 7.1% | 11.7% | 11.6% | 13.3% | 16.2% | 10.1% | 18.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TECH's financial statements (latest annual report filed August 24, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TECH financial results
In fiscal year 2026 (ended June 30, 2026), Bio-Techne reported revenue of $1.2 billion, down 0.4% from the year before. It had net income of $181.9 million (up 147.8%), a net profit margin of 15.0%. Diluted earnings per share came to $1.84. Over five years revenue grew at an average rate of 5.5% a year.
See the TECH stock overview for the latest quote and news, or the TECH chart for price history and technical indicators.
TECH income statement FAQ
What is Bio-Techne's annual revenue?
Bio-Techne reported total revenue of $1.2 billion for fiscal year 2026, which ended on June 30, 2026. That was down 0.4% from $1.2 billion the previous year.
Is Bio-Techne profitable?
Yes. Bio-Techne reported net income of $181.9 million in fiscal 2026, a net profit margin of 15.0%; its operating margin was 20.7%.
What is Bio-Techne's gross margin?
Bio-Techne's gross margin was 65.8% in fiscal 2026: for every $100 of revenue, Bio-Techne kept $66 after the direct cost of its products and services.
How much does Bio-Techne spend on research and development?
Bio-Techne spent $94.8 million on research and development in fiscal 2026, 7.8% of revenue.
How fast is Bio-Techne growing?
Revenue grew 5.5% a year on average over the last five fiscal years, from $931.0 million to $1.2 billion.
What are Bio-Techne's earnings per share?
Bio-Techne earned $1.84 per diluted share in fiscal 2026, compared with $1.93 a year earlier.
When will Bio-Techne report its next earnings?
Bio-Techne is expected to report results for the quarter ending September 30, 2026 on November 4, 2026.
When does Bio-Techne's fiscal year end?
Bio-Techne's fiscal year ends in June. The latest annual report covers the year ended June 30, 2026 and was filed on August 24, 2026.